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The RUNX genes encode transcription factors in-
volved in development and human disease. RUNX1
and RUNX3 are frequently associated with leuke-
mias, yet the basis for their involvement in leukemo-
genesis is not fully understood. Here, we show that
Runx1;Runx3 double-knockout (DKO)mice exhibited
lethal phenotypes due to bone marrow failure and
myeloproliferative disorder. These contradictory
clinical manifestations are reminiscent of human
inherited bone marrow failure syndromes such as
Fanconi anemia (FA), caused by defective DNA
repair. Indeed,Runx1;Runx3DKOcells showedmito-
mycin C hypersensitivity, due to impairment of
monoubiquitinated-FANCD2 recruitment to DNA
damage foci, although FANCD2 monoubiquitination
in the FA pathway was unaffected. RUNX1 and
RUNX3 interact with FANCD2 independently of
CBFb, suggesting a nontranscriptional role for
RUNX in DNA repair. These findings suggest that
RUNX dysfunction causes DNA repair defect, be-
sides transcriptional misregulation, and promotes
the development of leukemias and other cancers.
INTRODUCTION
Runx proteins belong to a family of heterodimeric transcription
factors, PEBP2/CBF, that controls critical cell fate determination
in several lineages (Ito, 2008) and is composed of two subunits: a
DNA-binding a subunit, and a non-DNA-binding b subunit (Cbfb).
The a subunit in mammals is encoded by three Runx family
genes, namely Runx1, Runx2, and Runx3. RUNX1 or AML1 is
one of the most frequently mutated genes in human leukemias
(Ley et al., 2013; Osato, 2004; Speck and Gilliland, 2002).
RUNX3 and CBFB are also shown to be associated with leuke-mogenesis (Liu et al., 1993; Maddipoti et al., 2008). Furthermore,
recent findings showed the presence of RUNX1 and CBFB mu-
tations in breast cancer (Banerji et al., 2012) and RUNX3 involve-
ment in lung cancer (Lee et al., 2013).
Conditional knockout (cKO) of Runx1 results in transient he-
matopoietic stem cell (HSC) expansion and subsequent exhaus-
tion (Jacob et al., 2010; Motoda et al., 2007). Runx3 cKO mice
reveal a mild expansion of myeloid cells and HSCs when aged,
partially phenocopying Runx1 cKO mice (Wang et al., 2013b).
Because Runx family genes were expected to have a compensa-
tory mechanism, we generated hematopoietic-specific Runx1;
Runx3 double-knockout (DKO) mice. Strikingly, concurrent
disruption of Runx1 and Runx3 resulted in mouse lethality due
to bone marrow failure (BMF) or myeloproliferative disorder
(MPD). Such clinically opposing manifestations are also seen in
human inherited bone marrow failure syndromes (IBMFSs) that
are known to be caused by defective DNA damage repair. Fan-
coni anemia (FA) is the most common disease constituting
IBMFSs, characterized by progressive BMF and cancer predis-
position, being caused by the biallelic disruption of FA gene
products that participate in the repair of DNA interstrand cross-
links (ICLs) (Moldovan andD’Andrea, 2009). Interestingly, FA-like
clinical manifestations were recently reported in two human pa-
tients with chromosome 21q deletions in the region encompass-
ing RUNX1 (Byrd et al., 2011; Click et al., 2011). Because these
patients did not exhibit mutations in FA genes tested, it was sug-
gested that deletion of RUNX1 might be the cause for FA-like
clinical symptoms.
Thus, we interrogated whether the phenotypes of Runx1;
Runx3 DKO mice represented a FA-like manifestation. We
show that combined ablation of Runx1 and Runx3 in both
mice and human cell lines leads to FA phenotypes and
describe a role for RUNX in the recruitment of FANCD2, a cen-
tral protein of the ICL repair pathway. Interestingly, the DNA
repair function of Runx is independent of Cbfb, suggesting a
nontranscriptional role of Runx in DNA repair. Our findings
have unraveled a previously unappreciated intimate link be-
tween RUNX and FA.Cell Reports 8, 767–782, August 7, 2014 ª2014 The Authors 767
Figure 1. Runx1;Runx3 DKO Mice Display a BMF Phenotype or MPD
(A) Time courses of WBC, Plt, and Hb counts of individual Runx1;Runx3 WT (black lines; n = 16) and Runx1;Runx3 DKO (blue lines; n = 14) mice are shown.
(B) Kaplan-Meier survival curves ofRunx1;Runx3WT (black line; n = 16) andRunx1;Runx3DKO (blue line; n = 20)mice. The p value fromMantel-Cox test is shown.
Vertical ticks and open circles represent censored cases and MPD cases, respectively.
(C) Weight of spleen (left) and thymus (right) in BMF Runx1;Runx3 DKO mice. Mean ± SEM from four independent experiments is shown (WT, n = 4; DKO, n = 5).
(legend continued on next page)
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RESULTS
Adult Runx1;Runx3 DKO Mice Show Lethality due to
BMF or MPD
To examine the effects of Runx1 and Runx3 ablation in the he-
matopoietic system, Runx1fl/fl;Runx3fl/fl;Mx1-Cre+ and Runx1fl/fl;
Runx3fl/fl;Mx1-Cremice were generated and injected with poly-
inosinic-polycytidylic acid (pIpC) at 4 weeks of age to induce Cre
expression. Hereafter, these mice are referred to as Runx1;
Runx3DKOmice andRunx1;Runx3wild-type (WT)mice, respec-
tively. The deletion efficiency of floxed alleles after Cre ex-
pression was nearly complete in the bone marrow (BM) from
Runx1;Runx3 DKO mice (Figure S1A).
BMF Mice
Complete blood counts (CBCs) in peripheral blood (PB) were
monitored fortnightly. At 4 weeks after pIpC injection, 82% (14
out of 17) of Runx1;Runx3 DKOmice had decreased white blood
cell (WBC) and platelet (Plt) counts, compared to WT mice (Fig-
ure 1A, top and middle panels). Moreover, Runx1;Runx3 DKO
mice developed anemia, evident from decreased hemoglobin
(Hb) levels, at later time points (Figure 1A, bottom panel). These
mice, termedBMFRunx1;Runx3DKOmice, diedwithin 18weeks
postinduction (Figure 1B).
Necropsy of BMF Runx1;Runx3 DKO mice revealed smaller
spleen size and almost undetectable thymus (Figure 1C).
BM cellularity was slightly lower in BMF Runx1;Runx3 DKO
mice than WT mice (Figure 1D). Flow cytometric examina-
tion demonstrated that before BMF development, Runx1;
Runx3 DKO mice consistently showed decreased lymphoid
and erythroid populations, accompanied by a relative in-
crease in myeloid population, as compared to WT mice
(Figure 1E).
MPD Mice
Surprisingly, the remaining 18% (3 out of 17; represented by
open circles in Figure 1B) of theRunx1;Runx3DKOmice showed
high WBC counts of above 50 3 103/ml (Figure 1F). Flow cyto-
metric and morphological analyses of PB and BM cells from
these mice showed that high WBC counts were largely due to
expanded c-KitSca-1Mac-1+Gr-1/lowCD44+ myelocytes
with ring-shaped nuclei (Figures 1G and 1H). These data indicate
that the Runx1;Runx3 DKO mice succumbed to MPD or leuke-
mia. In a transplantation assay using BM cells from a diseased
mouse, leukocytosis was recapitulated only in a small number
of recipient mice with a long latency. Therefore, this phenotype
in Runx1;Runx3 DKO mice is more appropriately defined as
MPD, but not leukemia. Such mice are termed as MPD Runx1;
Runx3 DKO mice.(D) Total BM cellularity in BMF Runx1;Runx3 DKO mice. Mean ± SEM of number
DKO, n = 5).
(E) Frequencies of each lineage in BM from pre-BMF/MPD Runx1;Runx3 DK
B220+CD19+; T cells, CD3+; erythroid, Ter119+. Mean ± SEM from three indepen
(F) WBC, Hb, and Plt counts of BMF and MPD Runx1;Runx3 DKO mice. Mean ±
(G) Representative May-Gru¨nwald-Giemsa staining of PB and BM cells in MPD R
(H) Representative flow cytometric analysis of BM cells in MPD Runx1;Runx3 DK
(I) Schematic diagram illustrating the phenotypes of Runx1;Runx3 DKO mice. Ru
jected with pIpC. After Cre induction, these mice were termed Runx1;Runx3 DKO
have yet to develop either conditions were referred to as pre-BMF/MPD mice.
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001,Because Runx1;Runx3 DKO mice develop BMF or MPD only
after a time lapse, Runx1;Runx3 DKO mice at presymptomatic
stage are hereafter referred to as pre-BMF/MPD mice unless
otherwise stated (Figure 1I).
BMF in Runx1;Runx3 DKO Mice Is Preceded by
Paradoxical Hematopoietic Stem/Progenitor Cell
Expansion due to Multiple Mechanisms, including Wnt
Activation
To examine if the BMF in Runx1;Runx3 DKO mice was due to
defective hematopoietic stem/progenitor cells (HSPCs), the
c-Kit+Sca-1+Lineage (KSL) fraction in the pre-BMF/MPD
Runx1;Runx3 DKO mice was analyzed by flow cytometry and
was shown to be drastically increased in the BM and spleen (Fig-
ures 2A–2D). Gene expression profiles (GEPs) of Runx1;Runx3
DKO KSL cells were assessed to gain an insight into the mech-
anism(s) underlying the drastic expansion of KSL population.
Gene set enrichment analysis (GSEA) revealed that a key HSC
self-renewal pathway, the Wnt pathway (Mosca et al., 2013),
was activated in Runx1;Runx3 DKO KSL cells (Figure 2E),
whereas Wnt inhibitors and antagonists, such as Dkkl1 and
Sfrp factors (Cain and Manilay, 2013; Wang et al., 2013a), were
suppressed (Figure 2F). Wnt activation in Runx1;Runx3 DKO
cells can be conferred by the loss of direct suppression by
Runx proteins (Ito et al., 2008) or by transcriptional upregulation
of activators. For example, Fancl, which ubiquitinates and acti-
vates b-catenin (Dao et al., 2012), was upregulated (Figure 2G).
Luciferase assay further confirmed that RUNX1 and RUNX3 sup-
pressed the expression of Fancl in a DNA-binding- and dose-
dependent manner (Figure 2H). In addition, similar to Runx1
cKO HSCs (Motoda et al., 2007), GEPs and quantitative real-
time PCR showed upregulation of Bmi1, another important
HSC self-renewal factor.
Analysis of GEP data further demonstrated the downregula-
tion of critical HSC niche-related factors Cxcr4, Vcam-1, and
Robo4 in Runx1;Runx3 DKO KSL cells (data not shown). It is
plausible that the loss of niche-related factors led to detachment
of quiescent long-term (LT) HSCs in the niche, which in turn
caused an increase of rapidly cycling short-term (ST) HSCs.
Similar to Runx1 cKO mice (Jacob et al., 2010), the weakened
niche interaction is likely to be the basis for HSC expansion in
Runx1;Runx3 DKO mice. Consistently, further analysis revealed
decreased LT-HSC, accompanied by increased ST-HSC, within
the KSL fraction of Runx1;Runx3DKOmice (Figures 2I and S1B).
A decrease in multipotent progenitors (MPPs) was also
observed. Due to the massive expansion of Runx1;Runx3 DKO
KSL cells, frequencies of LT-HSCs and MPPs in the BM wereof cells in two femurs from five independent experiments is shown (WT, n = 5;
O mice at 4–5 weeks postinduction. myeloid, Mac-1+ and Gr-1+; B cells,
dent experiments is shown (WT, n = 4; DKO, n = 5).
SEM is shown (WT, n = 14; BMF DKO, n = 9; MPD DKO, n = 3).
unx1;Runx3 DKO mice.
O mice.
nx1fl/fl;Runx3 fl/fl;Mx1-Cre+ mice (and littermate controls; not shown) were in-
mice and eventually succumbed to BMF or MPD. Runx1;Runx3 DKOmice that
Student’s t test). See also Figure S1.
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greater than WT levels (Figure S1C). Examination of specific he-
matopoietic progenitor compartments in the BM showed an
increased granulocyte/macrophage progenitor (GMP) fraction
and decreased common myeloid progenitor (CMP) and mega-
karyocyte/erythroid progenitor (MEP) fractions within the
myeloid progenitor compartment (c-Kit+Sca-1Lineage) of
Runx1;Runx3 DKO mice (Figure 2I). However, lineage priming
toward GMPs was not observed in the KSL population of
Runx1;Runx3 DKO mice (data not shown). In addition, there
were decreased common lymphoid progenitor (CLP) cells in
the Runx1;Runx3 DKO BM.
GSEA demonstrated significant enrichment of leukemia stem
cell (LSC)-related genes (Eppert et al., 2011) in Runx1;Runx3
DKO KSL cells (Figure 2J). Therefore, combined depletion of
Runx1 and Runx3 appears to deregulate the core transcriptional
program that controls normal and malignant stem cell behavior,
including self-renewal capability, thereby contributing to the dra-
matic expansion of Runx1;Runx3 DKO KSL cells.
Stem Cell Exhaustion and Differentiation Blocks across
All Hematopoietic Lineages Lead to BMF in
Runx1;Runx3 DKO Mice
HSPC frequencies from BMF mice were quantified to study the
contradictory phenomenon of HSPC expansion culminating
into BMF. In BMF Runx1;Runx3 DKO mice, the expansion of
the BM KSL compartment significantly decreased by 5-fold
(p < 0.05, Student’s t test) from the initial 48.7-fold increase in
pre-BMF/MPD Runx1;Runx3 DKO mice, to an average of 9.6-
fold increase in BMF mice (Figures 2A, bottom panel, and 2B).
This progressive reduction in KSL cells indicated HSC exhaus-
tion similar to Runx1 cKO mice (Jacob et al., 2010).
The complete lack of blood production was too severe to
be explained by HSC exhaustion alone. Therefore, Runx1;
Runx3 DKO mice were examined for additional hematopoietic
defects. Flow cytometric analysis revealed significant matura-
tion blocks in B and T cell precursors from pre-pro-B stage
(B220+CD43+BP-1HSA) to early pro-B stage (B220+CD43+
BP-1HSA+) and within the double-negative (DN) population at
the DN1 (CD44+CD25) to DN2 (CD44+CD25+) transition (Fig-
ures 3A and 3B). An increase in CD41+CD61+ megakaryocytic
lineage cells was observed (Figure 3C, top). However, histolog-Figure 2. Runx1;Runx3 DKO Mice Exhibit an Initial Expansion, but Sub
(A and C) Flow cytometric analysis of the HSPC compartment in BM (A) and s
Lineage cells of pre-BMF/MPD Runx1;Runx3 DKOmice at 5 weeks postinductio
shown. Percentages shown are frequencies of parent population.
(B and D) Graphical representations of results presented in (A) and (C) are shown in
pre-BMF DKO, n = 4; BMF DKO, n = 2) (B) and spleen (n = 4/genotype) (D) is sh
(E and F) GSEA for Wnt pathway (E) andWnt inhibitors/antagonists (F). In the left v
represents leading edge genes. In the right view, a heatmap of the leading edge
q value and p value.
(G) Quantitative real-time PCR of murine Fancl in BM KSL cells. Mean ± SEM of
(H) Luciferase assay showing repression of Fancl gene expression by RUNX1 and
containing three RUNX-binding sites (red stars) was used. In the bottom view, me
is a RUNX1 mutant defective in DNA binding. TLE1 is a corepressor known to fu
(I) Flow cytometric analysis of individual HSPC compartments in Runx1;Runx3 D
gate is shown (n = 2/genotype). Representative data from one out of two indepe
(J) GSEA for LSC genes. See legends for (E) and (F).
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001,ical analysis revealed the loss of mature megakaryocytes with
large size and multinuclei concomitant with an accumulation of
smaller and paired CD41+ cells, indicating increased cytokinesis
of megakaryoblasts in Runx1;Runx3 DKO mice (Figure 3C, bot-
tom). Erythroblast differentiation was blocked at the pro-E
(Ter119intCD71hi) to EryB (Ter119hiCD71hi) transition (Figure 3D).
Interestingly, there was a significant expansion of Mac-1+
Gr-1/low immature granulocytes with ring-shaped nuclei in the
BM of Runx1;Runx3 DKO mice (Figure 3E). Because the expan-
sion of immature cells was accompanied by the reduction in
matureMac-1hiGr-1hi granulocytes, a blockage in terminal differ-
entiation in granulocytes is thought to occur in Runx1;Runx3
DKO mice. A summary of these results is provided in Figure 3F.
Briefly, combined loss of Runx1 and Runx3 inhibits the matura-
tion of lymphocytes, megakaryocytes, and erythrocytes at early
stages of development, whereas the blockage in granulocytes
was observed at a relatively late stage, accompanied by the
expansion of Mac-1+Gr-1/low cells. We conclude that differenti-
ation failure coupled with progressive stem cell exhaustion
contributed to BMF in Runx1;Runx3 DKO mice.
Differentiation Blocks, HSPC Expansion, and MPD in
Runx1;Runx3 DKO Mice Are Largely Cell Autonomous
To assess whether the phenotypes in Runx1;Runx3 DKO mice
were cell autonomous, bone marrow transplantations (BMTs)
were conducted. Congenic strains of the pan-hematopoietic
marker CD45were used to distinguish the origins of repopulating
cells (Figure 4A).
At 8weeks post-BMT, donor chimerisms reached90% in the
BM of recipient mice, and Runx1;Runx3 DKO-transplanted mice
had lower WBC, Hb, and Plt counts than Runx1;Runx3 WT-
transplantedmice (Figure 4B).Runx1;Runx3DKOdonor cells ex-
hibited a skewed composition toward fewer B and T cells and
more myeloid cells in the PB, BM, and thymus in the recipient
mice, compared to Runx1;Runx3 WT donor cells (Figures 4C
and 4D). Runx1;Runx3 DKO donor KSL cells displayed substan-
tial increase (Figure 4E; 14.7-fold increase), although less
remarkable as the 48.7-fold increase in the earlier-mentioned
non-BMT, pre-BMF/MPD Runx1;Runx3 DKO mice. The lethal
phenotypes were recapitulated in Runx1;Runx3 DKO-trans-
planted mice, albeit less drastic than that of the Runx1;Runx3sequent Exhaustion, in the HSPC Compartment
pleen (C) of Runx1;Runx3 DKO mice. Representative plots gated from viable
n (A, top panel, and C) and BMF Runx1;Runx3 DKOmice (A, bottom panel) are
(B) and (D), respectively. Mean ±SEMof frequency of KSL in the BM (WT, n = 5;
own.
iew, an enrichment plot and ranked list for the genes are shown. Black solid bar
genes is shown. Statistical significance is given as false discovery rate (FDR)
relative expression is shown (n = 3/genotype).
RUNX3 in U937 cells. In the top view, a construct with a Fancl promoter region
an ± SEM of triplicates in a representative experiment is shown. RUNX1 R174Q
nction as a cofactor for RUNX-mediated transcriptional suppression.
KO mice at 5 weeks postinduction. Mean ± SEM of percentages within parent
ndent experiments are presented.
Student’s t test). See also Figure S1.
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Figure 3. Differentiation Blocks Occur at
Specific Developmental Stages in All
Hematopoietic Lineages in Runx1;Runx3
DKO Mice
(A and B) Flow cytometric analysis of B cell pre-
cursors in the BM (A) and T cell precursors in
the thymus (B) of Runx1;Runx3 DKO mice at
6–8 weeks postinduction. Representative plots
gated from viable cells are shown. Percentages
shown are frequencies of parent gate.
(C) Top, flow cytometric analysis of megakaryo-
cytes in the BM of BMF Runx1;Runx3 DKO mice.
Representative plots gated from viable BM cells
are shown. Bottom view presents histological
analysis of the corresponding BMs showing CD41+
megakaryocytes (red arrowheads). Half-bones
were stained with anti-CD41 antibody (green) and
DAPI (blue). Representative magnified images are
depicted below.
(D and E) Flow cytometric analysis of erythroid
precursors (D) and myeloid cells (E) in the BM of
BMF Runx1;Runx3 DKO mice.
(F) Schematic diagram summarizing the results
shown in (A)–(E). Differentiation blocks (red lines)
occurred at specific developmental stages in
multiple lineages in the Runx1;Runx3 DKO mice.
The differentiation blocks ultimately led to the
failure in production of mature cells of the various
lineages (red arrows within yellow box). Changes in
the HSPC and precursor populations are also
indicated (red arrows outside yellow box).
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Figure 4. Differentiation Blocks and HSPC Expansion in Runx1;Runx3 DKO Mice Are Cell Autonomous
(A) Schematic diagram showing an overview of the BMT experiment. Prior to transplantation, floxed alleles were induced for excision in Runx1fl/fl;Runx3fl/fl;Mx1-
Cre and Runx1fl/fl;Runx3fl/fl;Mx1-Cre+ mice. A total of 1 3 106 donor BM cells from Runx1;Runx3WT and Runx1;Runx3 DKO mice (CD45.2/CD45.2) were then
transplanted, with 0.2 3 106 radioprotective BM cells (CD45.1/CD45.2), into sublethally irradiated C57BL/6 recipient mice (CD45.1/CD45.1). Two independent
transplantations were performed.
(B) WBC, Hb, and Plt counts of transplanted mice at 8 weeks post-BMT. Mean ± SEM is shown (WT, n = 12; DKO, n = 15).
(C and D) Frequency of each lineage in CD45.2/CD45.2 donor cells in PB (C), BM (D, left), and thymus (D, right) at 8 weeks post-BMT. myeloid, Mac-1+ and Gr-1+;
B cells, B220+CD19+; T cells, CD3+. Mean ± SEM is shown (WT, n = 13; DKO, n = 15 [C]; WT, n = 2; DKO, n = 3 [D]).
(E) Frequency of HSPCs in CD45.2/CD45.2 donor BM cells at 8 weeks post-BMT. In the left view, representative flow cytometry plots gated from viable
CD45.2+CD45.1Lineage cells are shown. Percentages shown are frequencies of parent gate. In the right view, mean ± SEM of frequency of KSL cells within the
CD45.2+CD45.1 population is shown (WT, n = 2; DKO, n = 3).
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test). See also Figure S2.DKO mice because longer time was required to exhibit the phe-
notypes. Together, these results indicate that the BMF and MPD
phenotypes in Runx1;Runx3 DKOmice were largely cell autono-
mous, with a minor contribution from non-cell-autonomous fac-
tors. Results from a similar BMT experiment where donor BM
cells from Runx1fl/fl;Runx3fl/fl;Mx1-Cre+ and Runx1fl/fl;Runx3fl/fl;
Mx1-Cre mice were transplanted prior to pIpC treatment led
to similar conclusions (Figure S2).
Absence of Runx1 and Runx3 Leads to Impaired ICL
Repair
The BMF and MPD manifestations in Runx1;Runx3 DKO mice
are reminiscent of human IBMFSs, whereby two contradictory
phenotypes in a single patient are caused by defective DNA
repair, which leads to either eradication of unrepaired damagedcells or the accumulation of tumor-promoting genetic muta-
tions. Therefore, Runx1;Runx3 DKO mice were interrogated
for defective DNA repair pathways leading to IBMFS. The
susceptibility to DNA damage stimuli was observed as more
Runx1;Runx3 DKO mice had succumbed to total body irradia-
tion (TBI) as compared to their WT counterparts (Figure 5A).
Correspondingly, persistent gH2AX foci indicative of increased
DNA damage were observed in Runx1;Runx3 DKO KSL cells
after in vitro irradiation (IR) (Figure 5B). Also, increased
gH2AX+ population was detected by flow cytometry analysis
(Figure S3A). Moreover, there was a greater fold reduction in
the percentage of KSL fraction after TBI (Figure S3B). Micronu-
clei (MN), an indicator of DNA damage, showed increased
accumulation in the PB cells of Runx1;Runx3 DKO mice after
TBI (Figure 5C). These results suggest that defective DNACell Reports 8, 767–782, August 7, 2014 ª2014 The Authors 773
Figure 5. Runx1;Runx3 DKO Cells Show Increased IBMFS-like Genetic Instability
(A) Survival of Runx1;Runx3 WT (n = 11) and Runx1;Runx3 DKO (n = 14) mice after total body IR. To avoid misinterpretation of lethality due to the spontaneous
phenotypes in Runx1;Runx3 DKOmice, we examined the effects of IR at 2 weeks post-IR. Mean ± SEM of percentage of mice that died 2 weeks after IR (5 Gy) is
shown. n.d., not detectable.
(legend continued on next page)
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repair in Runx1;Runx3 DKO mice is similar to that of patients
with IBMFS.
Because FA is the most common disease among the IBMFS
group of diseases and recent clinical reports suggest a link be-
tween Runx factors and FA, GEP data sets of BM KSL fractions
were analyzed to examine if Runx1;Runx3 DKO mice resembled
FA. GEP data from Fancc;Fancg DKO cells (Pulliam-Leath et al.,
2010) were compared to that of Runx1;Runx3 DKO cells. A
binary regression analysis was employed to generate a FA signa-
ture based on GEP data from Fancc;FancgWT and Fancc;Fancg
DKO BM cells. In accordance to the degree of FA phenotype,
Fancc;Fancg WT and Fancc;Fancg DKO mice have low and
high probability, respectively, of a FA phenotype. By employing
this FA signature, Runx1;Runx3 DKO samples showed higher
probability of having FA gene expression-based phenotype as
compared to Runx1;Runx3WT samples (Figure 5D). In addition,
GSEA using a gene set of downregulated genes in Fancc;Fancg
DKO BM cells demonstrated a significant enrichment with the
downregulated genes in Runx1;Runx3DKO samples (Figure 5E),
suggesting similarity between Runx1;Runx3 DKO mice and the
FA mouse model.
Because a hallmark of FA cells is hypersensitivity to ICL-
inducing agents, progenitor cells from Runx1;Runx3 DKO mice
were treated with mitomycin C (MMC). Runx1;Runx3 DKO cells
showed decreased survival upon treatment with MMC (Fig-
ure 5F), and cytogenetic analysis of treated Runx1;Runx3 DKO
cells exhibited increased chromatid and chromosomal breaks
(Figure 5G), which are consistent with FA phenotype.
To recapitulate the FA-associated phenotype in other cell
types, double knockdown (DKD) of RUNX1 and RUNX3 (RUNX1;
RUNX3 DKD) was achieved using a RNA-interference based
knockdown (KD) strategy. Well-established cell lines for the
study of FA, HeLa-S3, and HCT116 were used (Figure 5H). KD
did not cause changes in cell viability (data not shown) or cell-cy-
cle profiles (Figure S3C). RUNX1;RUNX3 DKD cells showed(B) Increased DNA damage in Runx1;Runx3 DKO BM cells after in vitro IR. In the
cells at 12 hr after IR (4 Gy). In the right panel, mean ± SEM of results presented
(C) Flow cytometric analysis of micronucleated cells in the PB of Runx1;Runx3 D
(1 Gy) is shown (WT, n = 2; DKO, n = 4). Representative data from one out of tw
(D) Similarity of Runx1;Runx3 DKO phenotypes with FA. Mouse FA signature is ge
against Fancc;Fancg DKO GEPs. The outcome of applying the FA signature on R
(E) GSEA of Fancc;Fancg DKO BM downregulated genes using Runx1;Runx3 W
(F) MMC sensitivity of BM myeloid progenitor cells (c-Kit+Sca-1Lineage) from
colony-forming unit-culture (CFU-C) numbers, given as percentage of untreated, i
presented.
(G) Cytogenetic analysis of Runx1;Runx3 DKO BM myeloid progenitor cells. In
chromatid/chromosomal breaks (red arrows) after 48 hr of MMC treatment are pre
0.05, Fisher’s exact test). In the right panel, mean ± SEM of the total number of ab
panel, mean ± SEM of the number of aberrations per abnormal metaphase is sh
experiments are presented.
(H) Expression of RUNX1 and RUNX3 inRUNX1KD,RUNX3KD, andRUNX1;RUN
or treated with 1 mM MMC for 24 hr. Western blots were probed with antibodies
(I) Survival of RUNX1;RUNX3 DKD HCT116 cells after MMC treatment. After 72 h
triplicates, and cell growth was measured after 5 days. Representative data fro
percent survival, given as percentage of untreated cells, is shown.
(J) Survival of RUNX1;RUNX3 DKD Jurkat cells after MMC treatment. After 48 hr
triplicates, and cell viability was measured. Representative data from one out of t
given as percentage of untreated cells, is shown.
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001,MMC hypersensitivity (Figure 5I), increasedMMC-induced chro-
mosomal breaks (Figure S3D), and elevated accumulation of MN
before and after MMC treatment (Figure S3E). Similar results
were obtained in a hematopoietic cell line: Jurkat (Figure 5J).
BRCA1KDcells were used as a positive control for the karyotype
and MN analyses (Figures S3D–S3F). Therefore, FA-like mani-
festations observed in Runx1;Runx3 DKO mice appear to be re-
produced at least in human hematopoietic and epithelial cells
tested, and they seemingly serve as a platform for further precise
molecular analysis.
RUNX1 and RUNX3 Are Dispensable for FANCD2/FANCI
Monoubiquitination but Essential for Full Formation of
FANCD2/BRCA1 Foci
Cells deal with ICLs by activating the ATR-dependent DNA dam-
age checkpoint. The activated FA core complex then catalyzes
FANCD2/FANCI monoubiquitination through FANCL ubiquitin
ligase. Monoubiquitinated FANCD2 (FANCD2-Ub) localizes to
sites of ICLs and forms nuclear foci, which act as scaffold for
the recruitment of downstream DNA repair proteins (Kee and
D’Andrea, 2010). Notably, monoubiquitination of FANCD2 is
necessary but insufficient for the formation of FANCD2 foci
because FANCD2 monoubiquitination and foci formation can
be uncoupled in specific contexts such as when Brca1, Snm1,
or Usp1 are knocked down (Kim et al., 2009; Mason and Sekigu-
chi, 2011). We interrogated four key steps of ICL repair in
RUNX1;RUNX3 DKD cells: DNA damage checkpoint, FANCD2/
FANCI monoubiquitination, FANCD2 foci formation, and homol-
ogous recombination (HR) repair. Cell-cycle analysis showed
that the extent of G2/M accumulation, as well as phosphorylation
of CHK1 and p53, was similar between control and RUNX1;
RUNX3 DKD samples after MMC treatment (Figures S4A and
S4B), suggesting intact ATR-mediated checkpoint activation.
Data from two cell lines (HeLa-S3 and HCT116) showed a
similar extent of FANCD2 and FANCI monoubiquitination,left panel, pictures show representative analyses of gH2AX foci in sorted KSL
in the left panel is shown (WT, n = 3; DKO, n = 4).
KO mice. Mean ± SEM of MN-positive cells in CD71+ RET population after IR
o independent experiments are presented.
nerated using binary regression analysis by comparing Fancc;FancgWTGEPs
unx1;Runx3 DKO mice is shown.
T and Runx1;Runx3 DKO GEPs. See legends for Figures 2E and 2F.
Runx1;Runx3 WT (black) and Runx1;Runx3 DKO (blue) mice. Mean ± SEM of
s shown. Representative data from one out of two independent experiments are
the far-left panel, representative metaphase spreads showing MMC-induced
sented. In the left panel, the percentage of abnormalmetaphases is shown (*p <
errations per metaphase is shown (**p < 0.01, Student’s t test). In the far-right
own (**p < 0.01, F test). Representative data from one out of two independent
X3DKDHCT116 cells. After 72 hr of siRNA treatment, cells were kept untreated
against RUNX1 and RUNX3.
r of siRNA treatment, cells were treated with various doses of MMC for 24 hr in
m one out of three independent experiments are presented. Mean ± SEM of
of siRNA treatment, cells were treated with various doses of MMC for 48 hr in
wo independent experiments are presented. Mean ± SEM of percent survival,
Student’s t test unless otherwise stated). See also Figure S3.
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measured by the ratio of monoubiquitinated versus unmodified
proteins, in RUNX1;RUNX3 DKD and control cells after expo-
sure to MMC (Figures 6A and S4C), suggesting intact ubiquitin
ligase activity of the FA core complex. Interestingly, whereas
24 hr of MMC exposure induced robust FANCD2 foci formation
in control cells, FANCD2 foci were not efficiently formed in
RUNX1;RUNX3 DKD cells (Figures 6B, 6C, and S5A). Defective
FANCD2 recruitment was more discernible when Triton X-100
pre-extraction of soluble FANCD2 was performed before
subsequent processing (Figure 6C). The defect was also
quantified using automated image analysis software (ImageJ)
(Figure 6D). The average fluorescence intensity of FANCD2
foci per cell was also reduced in RUNX1;RUNX3 DKD cells
(562 fluorescence units in control cells versus 362 fluorescence
units in RUNX1;RUNX3 DKD cells) (Figure 6E). Although some
RUNX1;RUNX3 DKD cells still retained FANCD2 foci, it seems
largely not due to low transfection efficiency of small interfering
RNAs (siRNAs). Using fluorochrome-labeled RUNX1 and
RUNX3 siRNAs, transfection efficiency was determined to
be higher than 92% (Figure S5B), and the RUNX proteins
were significantly depleted across all cells (Figures S5C
and S5D).
To independently confirm the above findings, a subcellular
biochemical approach was used to assess FANCD2 recruitment
(Figure S5E). Increasing amounts of FANCD2-Ub and FANCI
(FANCI-Ub and unmodified form) were retained in the chromatin
fractions of MMC-treated cells in a time-dependent manner (Fig-
ures 6F and S5F). Interestingly, a modest increase in RUNX1 and
RUNX3 levels was noted in fraction P2 upon MMC treatment,
suggesting that a portion of RUNX complexes relocates to chro-
matin after DNA damage (Figure 6F). Strikingly, the chromatin
recruitment of FANCD2 and FANCI was significantly lower in
MMC-exposed RUNX1;RUNX3 DKD cells as compared to con-
trol cells (Figure 6G). These results confirm that the depletion
of RUNX proteins leads to defective recruitment of FA proteins
to sites of damage.Figure 6. FANCD2 Foci Formation Is Defective in RUNX1;RUNX3-Depl
(A) FANCD2/FANCI monoubiquitination in RUNX1 KD, RUNX3 KD, and RUNX1;R
were exposed to 150 nM MMC for 24 hr. Western blots were probed with indica
(B and C) Immunofluorescence detection of FANCD2 foci in RUNX1;RUNX3 DKD
cells were treated with 150 nM MMC for 24 hr before fixing (B) or pre-extracted w
than ten foci/cell), whereas green arrowheads/arrow indicates FANCD2 foci ce
(D and E) Immunofluorescence detection of FANCD2 foci in RUNX1;RUNX3 DKD
RUNX3 siRNA oligonucleotides were plated on coverslips, exposed to MMC for 2
FANCD2. Images were captured and subjected to quantitative analysis by Ima
intensity of foci/cell (E).
(F) Subcellular biochemical fractionation of HeLa-S3 cells treated with MMC. Cel
processed further for biochemically distinct two fractions, namely chromatin-enri
with antibodies against KU80 or Tubulin as the loading control.
(G) Chromatin fractionation of FANCD2 and FANCI in RUNX1;RUNX3 DKD HeLa
were treated with 150 nM MMC for 24 hr, and chromatin-enriched fractions wer
(H) Immunofluorescence detection of BRCA1 and FANCD2 foci in RUNX1;RUN
treatment, cells were treatedwith 150 nMMMC for 24 hr before pre-extraction with
both FANCD2 and BRCA1 foci formation (FANCD2/BRCA1 foci+), whereas gree
foci). Scale bar, 5 mm.
(I) Measurement of HR in RUNX1;RUNX3 DKD and BRCA1 KD HeLa cells using
assay. Middle view shows a western blot analysis of RUNX1, RUNX3, and BRCA
I-SceI expression is shown.
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001,FANCD2 foci formation was also impaired at early time points
(Figure S5G). Moreover, single depletion of RUNX1 or RUNX3
did not result in FANCD2 localization defects (Figure S5H). The
observation that RUNX1;RUNX3 DKD samples showed defec-
tive FANCD2 recruitment at early time points indicated that this
defect might be related to an upstream signal that controls
the assembly of FANCD2-Ub foci. Recent studies using
Brca1D11/D11 murine cells have uncovered a role for Brca1 in
the control of FANCD2 foci formation during ICL repair, which
is independent of its role in HR (Bunting et al., 2012). Similar to
RUNX1;RUNX3 DKD, BRCA1 KD resulted in reduced FANCD2
foci formation (Figures S5I and S5J), although BRCA1 depletion
does not affect the preceding FANCD2 monoubiquitination step
(Vandenberg et al., 2003). Upon MMC treatment of RUNX1;
RUNX3 DKD cells, all cells deficient for FANCD2 foci were
concurrently defective for BRCA1 foci formation (Figures 6H
and S5K).
To study if RUNX1;RUNX3 DKD led to downstream defects in
HR, the direct repeat-GFP (DR-GFP) reporter assay was used.
Transient expression of the rare-cutting endonuclease, I-SceI,
leads to double-strand breaks, and subsequent HR repair of
the breaks results in GFP+ cells that are quantifiable by flow
cytometry (Figure 6I, top). Because RUNX1;RUNX3 DKD cells
have a defect at the level of FANCD2 foci formation, the extent
of HR repair decreased by a mild 30% (Figure 6I). This pheno-
type is similar to the moderate defect in HR observed upon abla-
tion of core FA genes (Nakanishi et al., 2005; Yamamoto et al.,
2005). In contrast, consistent with an essential role of BRCA1
in HR, GFP positivity was drastically reduced by 90% in
BRCA1 KD cells.
RUNX1 and RUNX3 Control FANCD2 Recruitment to
Sites of ICLs in a Cbfb-Independent Manner
Heterodimerization of Runx with Cbfb is required for the protein
stability and transcriptional activities of Runx. Because GEP
analysis of Runx1;Runx3 DKO cells did not reveal obviouseted Cells
UNX3 DKD (RUNX DKD) HeLa-S3 cells. After 48 hr of siRNA treatment, cells
ted antibodies. L, long/monoubiquitinated form; S, short/unmodified protein.
HeLa-S3 cells. After 48 hr of ON-TARGET plus SMARTpool siRNA treatment,
ith Triton X-100 (C). Blue arrowhead/arrow indicates FANCD2 foci+ cell (more
lls. Scale bar, 5 mm.
HeLa-S3 cells. HeLa-S3 cells cotransfected with TAMRA-RUNX1 and DY647-
4 hr, pre-extracted with 0.5% Triton X-100, and stained with antibody against
geJ to measure the number of FANCD2 foci/cell (D) or average fluorescence
ls were exposed to MMC, and total cell extracts (TCE) were either prepared or
ched P2 and cytosolic/nucleoplasmic S2 fractions. Western blots were probed
-S3 cells. After 24 hr of ON-TARGET plus SMARTpool siRNA treatment, cells
e isolated. Western blots were probed with indicated antibodies.
X3 DKD HeLa-S3 cells. At 48 hr after ON-TARGET plus SMARTpool siRNA
0.25%Triton X-100 and fixation. Blue arrows indicate cells that are positive for
n arrows indicate cells that are negative for foci formation (FANCD2/BRCA1
DR-GFP assay. Top view shows a schematic diagram depicting the DR-GFP
1. In the bottom view, mean ± SEM of percentage of GFP+ cells at 72 hr after
Student’s t test). See also Figures S4 and S5.
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Figure 7. Interaction of RUNX1 and RUNX3 with FANCD2 Is Enhanced after MMC Treatment
(A) Kaplan-Meier survival curves ofCbfbWT (black dotted line, 5 Gy, n = 12; black solid line, 8 Gy, n = 11) andCbfb KO (blue dotted line, 5 Gy, n = 9; blue solid line,
8 Gy, n = 8) mice after total body IR. n.s. indicates not statistically significant p value using Mantel-Cox test. Vertical ticks represent censored cases.
(B and C) Coimmunoprecipitation of FANCD2 and FANCI with RUNX3 in HEK293T cells. EGFP-RUNX3 was overexpressed with FLAG-FANCD2 (B) or FLAG-
FANCI (C). Lysates were coimmunoprecipitated using GFP beads, and western blots were probed with indicated antibodies.
(legend continued on next page)
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transcriptional changes in DNA repair pathways (Callen et al.,
2013) (Figures S6A and S6B), we predicted that Runx1 and
Runx3 may function in a nontranscriptional capacity in DNA
damage response. In that case, although Runx-mediated tran-
scription would be largely abolished in Cbfb KO mouse, expo-
sure to DNA-damaging agents may not render a DNA damage
sensitivity phenotype. We generated Cbfb cKO mice in which
the deletion efficiency of floxed alleles after pIpC treatment
was nearly complete in the BM (Figure S6C). In contrast to
Runx1;Runx3DKOmice,Cbfb cKOmice did not show increased
sensitivity to TBI compared to CbfbWT mice (Figure 7A). More-
over, Cbfb cKO mice did not develop BMF or MPD (n = 9,
8months old), although other phenotypes, namely HSPC expan-
sion and differentiation blocks (unpublished data), were similar to
the Runx1;Runx3 DKO mice. Because Cbfb ablation largely
abolishes the transcriptional activity of all Runx proteins, the
above observation strongly suggests that RUNX may function
in DNA repair through mechanisms distinct from its canonical
transcriptional role.
Independent from the above-mentioned experiments, quanti-
tative mass spectrometric analysis to discover RUNX3-interact-
ing proteins identified FANCI as one of the high-confidence
interactors (unpublished data). We examined whether RUNX
canexercise its nontranscriptional role inDNA repair byphysically
associating with FANCD2-containing complexes. RUNX3 coim-
munoprecipitated with exogenous and endogenous FANCD2
and FANCI (Figures 7B–7D), whereas Cbfb failed to do so,
although it interacted with endogenous RUNX3 (Figure 7D), sug-
gesting thatCbfbwasnot incorporated intosuchDNArepair com-
plexes. Similar results were obtained for RUNX1. These data
suggest that the fraction of RUNX that exists in a complex with
FANCD2 is mutually exclusive from the RUNX/Cbfb complex.(D) Coimmunoprecipitation of endogenous FANCD2 and FANCI with RUNX3, but
EGFP-expressing plasmids were overexpressed in HEK293T. Lysates were co
indicated antibodies.
(E and F) Coimmunoprecipitation of endogenous FANCD2 with RUNX3 and RUN
EGFP-RUNX1 (F) was overexpressed and left untreated or exposed to 1 mMMMC
were probed with indicated antibodies. Blots were probed for phosphorylation o
(G) Coimmunoprecipitation of endogenous FANCD2 with endogenous RUNX1 an
MMC for 16 hr. Coimmunoprecipitation was performed by incubating 1mg of nuc
with indicated antibodies.
(H) Increased DNA damage in Runx1;Runx3 DKO BM cells without DNA damage
gH2AX foci is shown (n = 2/genotype).
(I) Flow cytometric analysis of micronucleated cells in the PB of Runx1;Runx3 DK
RET population is shown (n = 2/genotype). Representative data from one out of
(J) Survival ofRUNX1-ETOKD Kasumi-1 cells after MMC treatment. In the left pan
PCR analysis. Mean ± SEM of RUNX1-ETO expression is shown. In the right pane
measured. Representative data from one out of two independent experiments are
cells, is shown.
(K) FANCD2 monoubiquitination in RUNX1-ETO KD Kasumi-1 cells. After 24 hr o
extracts were prepared. Western blots were probed with indicated antibodies. Re
L, long/monoubiquitinated form; S, short/unmodified protein.
(L) FANCD2 in chromatin fraction fromRUNX1-ETOKDKasumi-1 cells. After 24 hr
enriched fractions (P2) were isolated. Western blots were probed with indicated a
are presented.
(M) Survival of RUNX1-ETO KD Kasumi-1 cells after PARP inhibitor treatment. Ce
measured. Mean ± SEM of percent survival, given as percentage of untreated ce
(N) Survival of Kasumi-1 cells after single or combined treatment with MMC and P
48 hr, and cell viability was measured. Mean ± SEM of percent survival, given as
Asterisk(s) represents significant differences (*p < 0.05, **p < 0.01, ***p < 0.001,To study if MMC treatment stimulated the interaction of
RUNX1 and RUNX3 to FANCD2, subnuclear distribution of these
proteins was examined. Upon MMC treatment, a fraction of
RUNX1 foci colocalized with FANCD2 foci (Figure S6D). Because
most RUNX proteins are localized to transcription-associated
nuclear matrix foci (Zaidi et al., 2002), it was difficult to correctly
estimate the percentage of colocalization with FANCD2 foci.
However, coimmunoprecipitation assays clearly revealed an
increased association between RUNX3 and FANCD2 after
MMC treatment (Figures S6E andS6F). Identical results were ob-
tained when the association of overexpressed RUNX3 or RUNX1
with endogenous FANCD2 was examined after exposure to
MMC (Figures 7E and 7F). Physiological relevance of RUNX-
FANCD2 interaction was further ascertained by endogenous
immunoprecipitation of RUNX1/RUNX3/FANCD2 complexes
from MMC-exposed nuclear extracts of Jurkat cells (Figure 7G).
Consistent with Cbfb-independent interaction between RUNX
and FANCD2, Cbfb does not bind to FANCD2 even after expo-
sure with MMC (Figure S6G).
We conclude that defective DNA repair contributes to the
lethal phenotypes in Runx1;Runx3 DKO mice. This was con-
firmed by increased basal levels of DNA damage inRunx1;Runx3
DKO cells as assessed by increased gH2AX staining in BM cells
(Figure 7H) and increased MN in PB reticulocytes (RETs)
(Figure 7I).
RUNX1-ETO Fusion Protein Causes the Defect in the FA
DNA Damage Repair Pathway
Finally, we studied the clinical relevance of RUNX participation in
DNA damage repair using hematopoietic cell lines carrying
RUNX alteration. Kasumi-1 is a RUNX1-ETO fusion gene-ex-
pressing human leukemic cell line, in which the fusion proteinnot Cbfb, in HEK293T cells. GFP-tagged Cbfb, EGFP-tagged RUNX3, or empty
immunoprecipitated using GFP beads, and western blots were probed with
X1 is enhanced after MMC treatment in HEK293T cells. EGFP-RUNX3 (E) or
. Cell lysates were coimmunoprecipitated using GFP beads, and western blots
f p53 (ser15) as an indicator of MMC addition.
d RUNX3. Nuclear extracts isolated from Jurkat cells were treated with 0.5 mM
lear extract with anti-RUNX antibody for 4 hr at 4C.Western blots were probed
stimulation. Mean ± SEM of percentage of KSL cells with indicated numbers of
O mice without DNA damage stimulation. Mean ± SEM of MN-positive cells in
two independent experiments are presented.
el, after 48 hr of siRNA treatment, cells were harvested for quantitative real-time
l, cells were treated with various doses of MMC for 48 hr, and cell viability was
presented. Mean ± SEM of percent survival, given as percentage of untreated
f siRNA treatment, cells were exposed to 2 mM MMC for 24 hr, and total cell
presentative data from one out of two independent experiments are presented.
of siRNA treatment, cells were treatedwith 2 mMMMC for 24 hr, and chromatin-
ntibodies. Representative data from one out of two independent experiments
lls were treated with various doses of Olaparib for 48 hr, and cell viability was
lls, is shown.
ARP inhibitor. Cells were treated with 1.5 mMMMC and/or 20 mMRucaparib for
percentage of untreated cells, is shown.
Student’s t test). See also Figure S6.
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is thought to suppress the expression and/or function of both
RUNX1 and RUNX3 simultaneously. Thus, the expression of
RUNX1-ETO is expected to cause defective DNA damage
repair and a DNA damage-hypersensitive phenotype. We
confirmed that Kasumi-1 cells were indeed sensitive to MMC,
and the KD of RUNX1-ETO reduced this sensitivity (Figure 7J).
Similar behavior was seen in another RUNX1-ETO-expressing
leukemic cell line: SKNO-1 (data not shown). Moreover, whereas
FANCD2 monoubiquitination remained unaffected (Figure 7K),
depletion of RUNX1-ETO led to increased FANCD2 recruitment
to chromatin both in the absence and presence of MMC (Fig-
ure 7L). The above results suggest that RUNX1-ETO might
repress FANCD2 foci formation and ICL repair in human
leukemic cells.
One of the outcomes of FA pathway abnormality is defective
HR repair, which in turn becomes addicted to alternative DNA
repair pathways, such as nonhomologous end-joining and
base excision repair (BER). It was hence predicted that RUNX
dysfunction would sensitize cells to inhibition of BER-mediating
PARP-1 (Carey and Sharpless, 2011; Ellisen, 2011). Thus,
Kasumi-1 cells were treated with two PARP inhibitors: Olaparib
or Rucaparib. Parental Kasumi-1 cells were more sensitive to
PARP inhibitor, and the KD of RUNX1-ETO partially reduced
this sensitivity (Figure 7M; data not shown). The efficacy of
PARP inhibitor was further accentuated when cells were treated
with MMC, indicating that the synthetic lethal effects of PARP-1
inhibition andMMC exposure could potentially be considered for
targeting RUNX leukemia (Figure 7N).
DISCUSSION
The functional redundancy between Runx1 and Runx3 was
unveiled by the lethality in Runx1;Runx3 DKO mice due to
BMF, caused by multiple differentiation blocks and stem cell
exhaustion, or preleukemic condition, MPD, which were not
observed in the respective single cKO mice (Runx1 cKO, n =
36; Runx3 cKO, n = 35). We found that Runx1 and Runx3 play
important roles in DNA repair, particularly the FA pathway where
RUNX proteins facilitate the recruitment of FANCD2-Ub to sites
of DNA damage (Figure S7). This report illustrates a direct rela-
tionship between Runx family genes and the FA pathway. The
property of Runx1 and Runx3 in the FA pathway is independent
of their roles as transcription factors and appears to be a basis
for the antitumorigenic roles of Runx in leukemia and solid tumor
development.
The simultaneous occurrence of the two contradictory mani-
festations, BMF and MPD, in Runx1;Runx3 DKO mice was remi-
niscent of human IBMFS. Of the several types of IBMFSs, we
focused on FA because recent reports described that chromo-
some 21q deletion containing RUNX1 was found in two FA-like
patients. Using multiple approaches, we showed that ablation
of both Runx1 and Runx3 led to defective DNA repair. These re-
sults suggest thatRUNX1 deletionmight predispose the patients
to FA-like conditions. Just as compound deficiency of Runx3 in
addition to Runx1 was required for the FA-like phenotypes in
mice, additional genetic change(s) besides RUNX1 malfunction
is also considered to be required for the manifestation of FA-
like conditions in the human patients. SOD1, located within the780 Cell Reports 8, 767–782, August 7, 2014 ª2014 The Authorsdeleted chromosome 21q region, seems to be an interesting
candidate. SOD1 encodes a superoxide dismutase to detoxify
reactive oxygen species (ROS). Notably, SOD1 is suppressed
in FA cells, causing their hypersensitivity to oxidants and MMC
(Kumari et al., 2014). Identification of the deleted gene(s) respon-
sible for the FA-like phenotypes would provide us with profound
insights into RUNX function in the FA pathway. Recent techno-
logical advances have shown frequent deletions of chromosome
21q, including the RUNX1 locus, in patients with congenital syn-
dromic thrombocytopenia with leukemia predisposition. We pro-
pose that FA-like cellular features should be investigated in the
patients with syndromic thrombocytopenia.
Although Runx1;Runx3 DKO mice recapitulated FA pheno-
types, some discordances exist between Runx1;Runx3 DKO
mice and FA patients/mouse models. The HSC compartment
is usually decreased in FA but showed a massive expansion
before subsequent decline in the pre-BMF/MPD Runx1;Runx3
DKO mice. Therefore, the reasons for the HSC expansion were
extensively sought in Runx1;Runx3 DKO mice and were shown
to be attributable to multiple mechanisms, including (1)
increased HSC self-renewal capability due to the elevation of
Bmi1 and activation of the Wnt pathway, (2) the detachment
from niches responsible for HSC quiescence, and (3) increased
expression of LSC-associated genes. All of these abnormalities,
which are unlikely to be present in the cells of patients with FA,
seem to clarify the differences in HSC compartments. Alterna-
tively, it is possible that, at an early time point before clinical
onset of BMF, IBMFS patients or mouse models may show
HSC expansion to some extent as a compensatory increase in
response to loss of mature hematopoietic cells and subsequent
increased cytokine secretion as homeostatic machinery. This
kinetics scenario has not been carefully examined in human
patients or mouse models in earlier studies. Interestingly, one
of the FA mouse models, Usp1 KO mice, showed an increase
in the size of its HSC compartment (Parmar et al., 2010). Usp1
encodes ubiquitin-specific peptidase 1, a ubiquitin-specific pro-
tease that serves to deubiquitinate the FANCD2/FANCI hetero-
dimer. Therefore, the level of Fancd2-Ub was enhanced in
Usp1 KOmice. However, Fancd2 foci formation was abrogated,
resulting in MMC hypersensitivity of Usp1 KO cells. These simi-
larities in key phenotypes between Usp1 KO and Runx1;Runx3
DKO mice may help to further dissect RUNX functions in the
FA pathway.
RUNX1 is among the most prevalent leukemia genes, and
RUNX3 is also associated with human leukemias. Notably,
simultaneous suppression of the expression and/or function of
both RUNX1 and RUNX3 was shown in acute myeloid leukemia
with t(8;21) or inv(16) due to the fusion proteins (Cheng et al.,
2008;Meyers et al., 1996). Therefore, the DNA damage response
defects seen in Runx1;Runx3 DKO mice may also be the mech-
anistic basis for leukemogenesis in common human RUNX leu-
kemias. Our results clearly demonstrated that human leukemia
cell lines expressing the RUNX1-ETO fusion gene are sensitive
to MMC, at least partially in a fusion gene-dependent manner.
This sensitivity was further enhanced in the presence of PARP in-
hibitor. This treatment with PARP inhibitors, together with DNA
ICL and/or standard chemotherapy drugs, could be applied for
RUNX leukemia. Because deregulation in RUNX family genes
is now found in a wide spectrum of cancers, this combined ther-
apy can potentially be extended to common cancers.
EXPERIMENTAL PROCEDURES
Mice
Runx1fl/fl (Taniuchi et al., 2002), Runx3fl/fl,Cbfbfl/fl (Naoe et al., 2007), andMx1-
Cre+ mice were backcrossed to mice in the C57BL/6 background for at least
three generations before being used for subsequent crosses. Animals carrying
both floxed Runx1 (Runx1fl/fl) and floxed Runx3 (Runx3fl/fl) alleles were crossed
with aMx1-Cre transgenic line to obtainRunx1fl/fl;Runx3fl/fl;Mx1-Cre+mice and
Runx1fl/fl;Runx3fl/fl;Mx1-Cre littermate controls on the C57BL/6 background.
Cbfbfl/fl;Mx1-Cre+ mice were obtained from similar crosses. All animal exper-
iments followed the guidelines set by the National Advisory Committee for
Laboratory Animal Research.
Cell Lines, Plasmids, and Transfection
Human embryonic kidney 293T (HEK293T), HCT116, and HeLa-S3 cell lines
were procured from American Type Culture Collection. Cells were cultured
by supplementing Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum. Plasmids encoding human FLAG-RUNX3, EGFP-RUNX3, EGFP-
RUNX1, and mouse EGFP-Cbfb were described earlier by Chuang et al.
(2012) and Yano et al. (2006), and a plasmid-encoding mouse FLAG-Cbfb
was constructed for the current study. HA-FLAG-tagged FANCI and FLAG-
FANCD2were kindly provided by A. Smogorzewska andN.Matsushit, respec-
tively. HeLa-S3 stably integrated with DR-GFP was a kind gift from J. Parvin.
For overexpression experiments in HEK293T, TransIT-293 transfection re-
agent was used according to the manufacturer’s instructions.
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